DRUG	SUPPLIED	DOSE	COMMENTS
CASPOFUNGIN (Paeds) (Cancidas) Mechanism of action: Echinocandin antifungal Ref: 6, 44, 68, 93, 263, 264, 612 Last update: 2022-06-15	Injection: 50 mg/vial	Fungal Prophylaxis and Treatment Infants <3 mos: 25 mg/m2/dose IV once daily Children 3 mo to 17 yrs: Loading dose: 70 mg/m2/dose IV on day 1 (max 70 mg/dose) Maintenance: 50 mg/m2/dose IV once daily (max 50 mg/dose). May increase to 70 mg/m2/dose IV daily (max 70 mg) if clinical response is inadequate Adults: Loading dose: 70 mg IV on day 1 Maintenance: 50 mg IV once daily. May increase to 70 mg IV daily if clinical response is inadequate	Dose adjustment may be required in hepatic impairment; see Parenteral Manual monograph. Caspofungin levels/effects may be increased with concurrent use of cyclosporine and decreased with rifampin. Caspofungin may reduce AUC of tacrolimus by ~20%. Adverse effects include: elevated transaminases, fever, rash, pruritis, phlebitis, headache, GI symptoms, anemia. Achieves low levels in CSF; caspofungin is not recommended for CNS disease. Less than 2% of dose is excreted into urine in unchanged form; treatment failures of candiduria due to potentially subtherapeutic concentrations in urine have been reported. Standard Prescription: caspofungin__mg IV Q__H (__mg/m2/day)